Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
Stefania Chiappini, Rachel Vickers‐Smith, Daniel R. Harris, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 994-994
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Association of semaglutide with risk of suicidal ideation in a real-world cohort
William Wang, Nora D. Volkow, Nathan A. Berger, et al.
Nature Medicine (2024) Vol. 30, Iss. 1, pp. 168-176
Open Access | Times Cited: 102
Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality
Georgios Schoretsanitis, Stefan Weiler, Corrado Barbui, et al.
JAMA Network Open (2024) Vol. 7, Iss. 8, pp. e2423385-e2423385
Open Access | Times Cited: 21
Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database
Rosanna Ruggiero, Annamaria Mascolo, Angela Spezzaferri, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 147-147
Open Access | Times Cited: 18
Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis
Amira Guirguis, Stefania Chiappini, GD Papanti P, et al.
European Neuropsychopharmacology (2024) Vol. 82, pp. 82-91
Open Access | Times Cited: 18
Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement
Kariem El‐Boghdadly, Jugdeep Dhesi, Philippa Fabb, et al.
Anaesthesia (2025)
Open Access | Times Cited: 4
Semaglutide: Nonarteritic Anterior Ischemic Optic Neuropathy in the FDA adverse event reporting system – A disproportionality analysis
Marina Azab, Luca Pasina
Obesity Research & Clinical Practice (2025)
Closed Access | Times Cited: 3
GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach
Davide Arillotta, Giuseppe Floresta, Amira Guirguis, et al.
Brain Sciences (2023) Vol. 13, Iss. 11, pp. 1503-1503
Open Access | Times Cited: 37
Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
Wenchao Lu, Shihan Wang, Huilin Tang, et al.
European Psychiatry (2025) Vol. 68, Iss. 1
Open Access | Times Cited: 1
Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry
Hubertus Himmerich, Susan L. McElroy
Journal of Clinical Psychopharmacology (2024)
Closed Access | Times Cited: 6
Exploring the Relationship between Opium Consumption and Lipid Profiles: A Population-Based Study of 10,663 Individuals in Southern Iran.
Najibullah Baeradeh, Seyed Vahid Hosseini, Leila Moftakhar, et al.
Clinical Epidemiology and Global Health (2025) Vol. 32, pp. 101920-101920
Closed Access
Glucagon-like-peptide-1-Rezeptoragonisten: eine neue pharmakologische Behandlungsoption für psychiatrische Erkrankungen?
Hubertus Himmerich
Der Nervenarzt (2025)
Open Access
Auswirkungen „neuer“ Antidiabetika auf das Anästhesiemanagement
Bernd Rupprecht, C. Dumps
Die Anaesthesiologie (2025)
Closed Access
Neurocircuitry underlying the actions of glucagon-like peptide 1 and peptide YY3–36 in the suppression of food, drug-seeking, and anxiogenesis
Yasmina Dumiaty, Brett M. Underwood, Jenny Phy-Lim, et al.
Neuropeptides (2024) Vol. 105, pp. 102427-102427
Open Access | Times Cited: 4
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Measures of Suicidality A Systematic Review
Kyle Valentino, Kayla M. Teopiz, William W. L. Cheung, et al.
Journal of Psychiatric Research (2025) Vol. 183, pp. 112-126
Open Access
Prescribing patterns of glucagon-like peptide-1 receptor agonists in the Swedish capital region—a register-based cross-sectional study
Annica Fors, Tomas Forslund, Anders Sundström, et al.
European Journal of Clinical Pharmacology (2025)
Open Access
Semaglutide Misuse in Atypical Anorexia Nervosa—A Case Report
Anna I. Guerdjikova, Anna Ward, Mack Ontiveros, et al.
Journal of Clinical Psychopharmacology (2024)
Closed Access | Times Cited: 3
An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database
Anca Butucă, Carmen Maximiliana Dobrea, Anca Maria Arseniu, et al.
(2024)
Open Access | Times Cited: 2
An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database
Anca Butucă, Carmen Maximiliana Dobrea, Anca Maria Arseniu, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1124-1124
Open Access | Times Cited: 2
Exploring Human Misuse and Abuse of Veterinary Drugs: A Descriptive Pharmacovigilance Analysis Utilising the Food and Drug Administration’s Adverse Events Reporting System (FAERS)
Josie Dunn, Fabrizio Schifano, Ed Dudley, et al.
Toxics (2024) Vol. 12, Iss. 11, pp. 777-777
Open Access | Times Cited: 2
Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review
Ali El-Solh, Erin Gould, Keziah Aibangbee, et al.
Expert Opinion on Pharmacotherapy (2024)
Closed Access | Times Cited: 2
Exploring the nexus of binge eating disorder (BED), New Psychoactive Substances (NPS), and misuse of pharmaceuticals: charting a path forward
Stefania Chiappini, Guy Pelletier, Rachel Vickers‐Smith, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 18, pp. 1915-1918
Open Access | Times Cited: 6
Post-marketing risk analysis of bendamustine: a real-world approach based on the FAERS database
Dan Li, Yuan Zhang, Jia Qi Ni, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Anti-obesity Drugs for the Treatment of Binge Eating Disorder: Opportunities and Challenges
Ilaria Riboldi, Giuseppe Carrà
ALPHA PSYCHIATRY (2024) Vol. 25, Iss. 3, pp. 312-322
Open Access | Times Cited: 1
Adverse events of tissue plasminogen activators in acute myocardial infarction patients: a real-world and pharmacovigilance database analysis
Fangying Liu, Yang Guo, Jia Xie, et al.
BMC Cardiovascular Disorders (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Movement disorders related to antidiabetic medications: a real-world pharmacovigilance study
Yingjie Zhao, Fei Lu, Yongtao Duan
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 135, pp. 111128-111128
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top